

Atty. Dkt. No. 018861-0216

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ali I. FATTOM et al.

Title: GLYCOCONJUGATE VACCINES FOR USE IN IMMUNE-COMPROMISED POPULATIONS

Appl. No.: 09/955,585

Filing Date: 09/19/2001

Examiner: Patrica A. Duffy

Art Unit: 1645

AMENDMENT TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a previous assertion of Small Entity status.

☐ Assertion of Small Entity status is enclosed.

☒ The fee required for additional claims is calculated below:

| | Claims As Amended | | Previously Paid For | | Extra Claims Present | | Rate | | Additional Claims Fee |
|--|-------------------------|---|------------------------|---|----------------------------|---|---------|----------|--------------------------|
| Total Claims: | 7 | - | 20 | = | 0 | x | \$18.00 | = | \$0.00 |
| Independent Claims: | 1 | - | 3 | = | 0 | x | \$88.00 | = | \$0.00 |
| First presentation of any Multiple Dependent Claims: | | | | | | | + | \$300.00 | = \$0.00 |
| CLAIMS FEE TOTAL | | | | | | | | = | \$0.00 |

- ☐ Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

| | | |
|--|------------|--------|
| <input type="checkbox"/> Extension for response filed within the first month: | \$110.00 | \$0.00 |
| <input type="checkbox"/> Extension for response filed within the second month: | \$430.00 | \$0.00 |
| <input type="checkbox"/> Extension for response filed within the third month: | \$980.00 | \$0.00 |
| <input type="checkbox"/> Extension for response filed within the fourth month: | \$1,530.00 | \$0.00 |
| <input type="checkbox"/> Extension for response filed within the fifth month: | \$2,080.00 | \$0.00 |
| EXTENSION FEE TOTAL: | | \$0.00 |
| <input type="checkbox"/> Statutory Disclaimer Fee under 37 C.F.R. 1.20(d): | \$110.00 | \$0.00 |
| CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL: | | \$0.00 |
| <input type="checkbox"/> Small Entity Fees Apply (subtract ½ of above): | | \$0.00 |
| TOTAL FEE: | | \$0.00 |

- ☐ Please charge Deposit Account No. 19-0741 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date


October 22, 2004

FOLEY & LARDNER LLP
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By

Courtenay C. Brinckerhorr

Courtenay C. Brinckerhorr
Attorney for Applicant
Registration No. 37,288



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ali I. FATTOM *et al.*
Title: GLYCOCONJUGATE VACCINES FOR USE IN
IMMUNE-COMPROMISED POPULATIONS
Appl. No.: 09/955,585
Filing Date: September 19, 2001
Examiner: DUFFY
Art Unit: 1645

**RESPONSE TO NON-RESPONSIVE AND
AMENDMENT AND REPLY UNDER 37 CFR § 1.111**

Mail Stop NON-FEE AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

This communication is responsive to the Non-Responsive Communication dated October 18, 2004, concerning the above-referenced patent application.

Amendments to the Specification begin on page 2 of this document.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this document.

Remarks/Arguments begin on page 5 of this document.

Please amend the application as follows: